Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

Antengene to Begin Phase I Clinical Study of ATG-022 for Advanced Solid Tumors

Fineline Cube Mar 14, 2023

China-based Antengene Corporation Ltd (HKG: 6996) is poised to commence a Phase I clinical study...

Company Drug

Guangdong Zhongsheng’s RAY1225 Receives NMPA Approval for Clinical Study

Fineline Cube Mar 14, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received approval...

Company Deals

AnnJi Pharma Signs USD 250 Million Licensing Deal with Avenue Therapeutics for Kennedy’s Disease Drug

Fineline Cube Mar 14, 2023

Taiwan-based AnnJi Pharmaceutical Co., Ltd has announced the signing of a licensing agreement with US...

Company Drug

Vcanbio’s VUM02 Gains CDE Review for Liver Failure and ARDS Clinical Trials

Fineline Cube Mar 14, 2023

Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that two additional clinical...

Company Drug

Luye Pharma’s Biosimilar BA9101 Completes Phase III Study Enrollment with Ocumension

Fineline Cube Mar 14, 2023

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has completed...

Company Deals

Immunophage Biotech Raises RMB 200 Million in Series B1 Financing for Clinical Trials

Fineline Cube Mar 14, 2023

Nanjing-based Immunophage Biotech Co., Ltd reportedly raised close to RMB 200 million (USD 29.1 million)...

Company Drug

Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer

Fineline Cube Mar 14, 2023

China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...

Company Drug

CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing

Fineline Cube Mar 14, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...

Deals R&D

Pasteur Institute Suspends Joint Venture with Chinese Academy of Sciences

Fineline Cube Mar 14, 2023

France’s Pasteur Institute has announced its decision to suspend its joint-venture (JV) partnership with the...

Company Medical Device

Boston Scientific Launches REPLACE Study for FARAPULSE PFA System in China

Fineline Cube Mar 14, 2023

US-based medical technology major Boston Scientific Corporation (NYSE: BSX) has announced the initiation of the...

Company Drug

Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan

Fineline Cube Mar 13, 2023

Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...

Company Deals

Silicon Valley Bank Collapse Impacts Tech and Biotech Sectors Globally

Fineline Cube Mar 13, 2023

The tech and biotech sectors are grappling with the implications of the collapse of US-based...

Company Deals

Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development

Fineline Cube Mar 13, 2023

Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised...

Company Deals

XtalPi and Chia Tai Tianqing Achieve Phase II Milestone in Cancer Drug Development

Fineline Cube Mar 13, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has partnered with China’s Chia Tai Tianqing to...

Company Deals

Overland Pharmaceuticals Partners with GoBroad Healthcare to Strengthen Cell Therapy Research

Fineline Cube Mar 13, 2023

China-based firm Overland Pharmaceuticals has entered into a strategic partnership with GoBroad Healthcare Group to...

Company Drug

Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806

Fineline Cube Mar 13, 2023

Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...

Company Drug

CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine

Fineline Cube Mar 13, 2023

China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...

Company Deals

Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development

Fineline Cube Mar 13, 2023

China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100...

Company Deals

Livzon Pharmaceutical Secures Exclusive Rights to Onconic’s GERD Treatment Zastaprazan

Fineline Cube Mar 13, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with South Korean...

Company Drug

CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting

Fineline Cube Mar 13, 2023

China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...

Posts pagination

1 … 575 576 577 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.